Zevra Therapeutics Presents Four Abstracts on MIPLYFFA at WORLDSymposium.

Zevra Therapeutics announced four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation at the 22nd Annual WORLDSymposium. Dr. Caroline Hastings will present four-year real-world safety and efficacy data of MIPLYFFA in patients with Niemann-Pick Disease Type C (NPC). The poster presentations include outcomes from the U.S. Early Access Program (EAP), multi-year subgroup analyses, and efficacy results from a randomized trial.